H2 Blockers and Vitamin B12: Does Famotidine Affect B12 Levels?
The connection between proton pump inhibitors and vitamin B12 depletion is relatively well-known. Less discussed is that H2 receptor antagonists — famotidine (Pepcid), cimetidine (Tagamet), ranitidine (Zantac, before its recall), and nizatidine (Axid) — work through the same basic mechanism and create the same risk, just to a lesser degree. Both drug classes reduce gastric acid. Both impair the acid-dependent step that releases dietary B12 from food proteins. For people who rely on H2 blockers chronically, this is worth understanding.
Why B12 absorption depends on stomach acid
Vitamin B12 in food — meat, dairy, eggs — arrives bound to proteins. Before it can be absorbed, it must be released from those proteins in the stomach. Gastric acid and the enzyme pepsin (which itself requires an acidic environment to activate) accomplish this step. Once free, B12 binds to a carrier called intrinsic factor, which is secreted by the same parietal cells that produce acid. The B12-intrinsic factor complex then travels to the ileum, where it is absorbed.
H2 receptor antagonists block histamine H2 receptors on gastric parietal cells, which reduces but does not eliminate acid secretion. Without enough acid, the protein-unbinding step is impaired. Some B12 remains attached to food proteins and passes through the gut without being absorbed.
Proton pump inhibitors are more thorough. They irreversibly block the proton pump itself, suppressing acid secretion more completely and over a longer period than H2 blockers. This is why PPI-related B12 malabsorption is better-documented and generally more severe. H2 blockers produce a similar but milder version of the same problem.
Who is most affected — and who is not
The critical distinction for supplementation is between dietary B12 and crystalline B12. Dietary B12 requires acid-mediated protein release. Crystalline B12 — the form in tablets, sublingual preparations, and most supplements — is already free of protein binding. It requires intrinsic factor for absorption but not gastric acid. This means that someone on an H2 blocker who takes a B12 supplement absorbs that supplement substantially normally, while their absorption from a steak or a glass of milk is somewhat impaired.
Practically, this matters most for people who depend heavily on food sources of B12 and do not supplement — particularly older adults, who already tend toward lower B12 levels as intrinsic factor production declines with age, and people with limited animal product intake. For people who already take a B12 supplement, chronic H2 blocker use is unlikely to produce deficiency.
The NIH ODS Vitamin B12 fact sheet identifies both H2 blockers and PPIs as recognized causes of B12 malabsorption with prolonged use, noting that the interaction is well-established enough to warrant awareness in clinical practice. Short-term or intermittent use — taking famotidine for occasional heartburn rather than daily — is unlikely to produce meaningful depletion.
A note on ranitidine
Ranitidine (Zantac) was recalled in 2020 due to the presence of N-nitrosodimethylamine (NDMA), a probable carcinogen, at levels that increase over time with storage. This recall was unrelated to the B12 interaction — it was a manufacturing and chemical stability issue specific to ranitidine, not a class-wide concern for H2 blockers. Famotidine and cimetidine were not recalled and remain in use. The B12 interaction applies to all H2 blockers through the same acid-reduction mechanism.